BioSpace News Archive

Navidea Biopharmaceuticals, Inc. today announced its financial results for the fourth quarter and year-to-date for the period ended December 31, 2021.

Ocugen, Inc. today announced the appointment of Marna C. Whittington, PhD, to the Board of Directors. Her term became effective March 21, 2022.

Crescita Therapeutics Inc. today reported its financial results for the three months and fiscal year ended December 31, 2021 (“Q4-F2021” and “F2021”).

Totus Medicines today announced the hiring of Laura Miller as the company’s first Chief Business Officer (CBO)/Chief Operating Officer (COO).

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced the initiation of a Phase 1 study of RT-102, an oral formulation of the human parathyroid hormone analog PTH(1-34) for the treatment of osteoporosis, delivered via RaniPill™ capsule.

Recursion (Nasdaq: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2021.

electroCore, Inc., a commercial-stage bioelectronic medicine company, announced its co-founder and Chief Medical Officer, Dr. Peter Staats, will keynote the Fifth Annual Bioelectronic Medicine Forum on April 5, 2022.

Histogen Inc. announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 2,500 shares of Series A redeemable convertible preferred stock and 2,500 shares of Series B redeemable convertible preferred stock.

Cerus Endovascular Ltd., a privately held, commercial-stage medical device company, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its 027 micro-catheters, available in two lengths, expanding its product portfolio which includes the already FDA cleared 021 micro-catheter platform.

Thermo Fisher Scientific Inc., the world leader in serving science, today announced its collaboration with the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) Initiative, Helix, and Rosalind aimed at developing a new genotyping method for SARS-CoV-2 that could speed up the identification of variants as they emerge.